Drug intelligence / Profile preview

chloroquine + methotrexate

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Chloroquine + methotrexate is a combination therapy used primarily for the treatment of rheumatoid arthritis. Methotrexate is a disease-modifying antirheumatic drug (DMARD) with anti-inflammatory and immunosuppressive effects, while chloroquine is an antimalarial agent that also has immunomodulatory properties. The combination has been shown to be slightly more efficacious than methotrexate alone or with placebo in reducing joint counts, improving grip strength, and enhancing functional ability in patients with rheumatoid arthritis. However, it may also be associated with increased toxicity compared to monotherapy[1][6].

Other names: MTX/CHLOmethotrexate and chloroquine

Targets

DHFR (Dihydrofolate reductase)ADOR (Adenosine receptors)

Beyond the preview

Go deeper on chloroquine + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chloroquine + methotrexate.

Explore the full profile